Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco S&P 500 Momentum ETF (SPMO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Invesco S&P 500 Momentum ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Invesco S&P 500 Momentum ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco S&P 500 Momentum ETF trades at $149.65, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc pays a 0.98% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

SPMOZBH
Sector
Broad Market / FactorHealth
52-Week High
$161.66$107.71
52-Week Low
$107.84$79.58
Market Cap
$18.65B
Enterprise Value
$25.72B
Dividend Yield
0.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco S&P 500 Momentum ETF

SPMO (Invesco S&P 500 Momentum ETF) trades at $149.69, up 0.4% with strong bullish momentum indicators. The ETF has demonstrated exceptional 2026 performance with 26% returns, significantly outperforming the S&P 500 while maintaining lower drawdowns. Technical analysis shows bullish moving averages but neutral oscillators, with RSI_6 at 88.22 suggesting potential overbought conditions. Recent institutional interest includes Alpha Zero LLC increasing its position by 6.4% to $10.73 million in Q1 2026.

The outlook remains positive given SPMO's momentum-driven strategy and concentrated tech exposure (55% weighting), particularly benefiting from AI-driven growth. However, risks include higher volatility during sector rotations and downside vulnerability if momentum factors reverse. The ETF's 0.13% expense ratio provides cost efficiency for momentum exposure, but investors should monitor concentration risks in technology holdings.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.

The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.

Returns comparison

Trailing returns across standard periods

About Invesco S&P 500 Momentum ETF

SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.

Read more on SPMO

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH